


ELQ-598

Cat. No.:	HY-163483
CAS No.:	3023709-99-8
Molecular Formula:	C ₂₈ H ₂₃ ClF ₃ NO ₆
Molecular Weight:	561.93
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ELQ-598, as a prodrug, is converted into the active drug ELQ-596 upon oral administration. ELQ-598 demonstrates potent parasitic growth inhibition capabilities (IC ₅₀ = 37 nM). ELQ-598 also shows low toxicity towards human cells (IC ₅₀ = 19 μM). ELQ-598 can be used for research into babesiosis ^[1] .																
In Vivo	<p>ELQ-598 (10 mg/kg; p.o.; daily DPI 3-7) achieves complete elimination of <i>B. duncani</i> infection in C3H mice^[1].</p> <p>ELQ-598 (10 mg/kg; p.o.; daily DPI 3-7) is effective at eliminating <i>B. microti</i> infection in mice^[1].</p> <p>ELQ-598 (10 mg/kg; p.o.; daily DPI 3-7) combined with atovaquone (HY-13832) can eliminate the infection in the C3H/HeJ mice infected with <i>B. duncani</i> and SCID mice model infected with <i>B. microti</i>^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C3H mice genetically prone to <i>B. duncani</i> infection^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o.; daily DPI 3-7</td> </tr> <tr> <td>Result:</td> <td>Resulted in a complete elimination of the parasites. Mice survived for the duration of the study with no recurrence of parasitemia observed.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>C3H/HeJ mice for <i>B. duncani</i> infection, and SCID mice for <i>B. microti</i> infection^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10mg/kg with 10mg/kg atovaquone,</td> </tr> <tr> <td>Administration:</td> <td>p.o.; daily DPI 3-7</td> </tr> <tr> <td>Result:</td> <td>All mice survived without any recurrence of parasitemia. A potent synergistic or additive effect of the drug combination in eradicating the lethal infection. This combination strategy offers enhanced efficacy compared to the use of either compound alone.</td> </tr> </table>	Animal Model:	C3H mice genetically prone to <i>B. duncani</i> infection ^[1]	Dosage:	10mg/kg	Administration:	p.o.; daily DPI 3-7	Result:	Resulted in a complete elimination of the parasites. Mice survived for the duration of the study with no recurrence of parasitemia observed.	Animal Model:	C3H/HeJ mice for <i>B. duncani</i> infection, and SCID mice for <i>B. microti</i> infection ^[1]	Dosage:	10mg/kg with 10mg/kg atovaquone,	Administration:	p.o.; daily DPI 3-7	Result:	All mice survived without any recurrence of parasitemia. A potent synergistic or additive effect of the drug combination in eradicating the lethal infection. This combination strategy offers enhanced efficacy compared to the use of either compound alone.
Animal Model:	C3H mice genetically prone to <i>B. duncani</i> infection ^[1]																
Dosage:	10mg/kg																
Administration:	p.o.; daily DPI 3-7																
Result:	Resulted in a complete elimination of the parasites. Mice survived for the duration of the study with no recurrence of parasitemia observed.																
Animal Model:	C3H/HeJ mice for <i>B. duncani</i> infection, and SCID mice for <i>B. microti</i> infection ^[1]																
Dosage:	10mg/kg with 10mg/kg atovaquone,																
Administration:	p.o.; daily DPI 3-7																
Result:	All mice survived without any recurrence of parasitemia. A potent synergistic or additive effect of the drug combination in eradicating the lethal infection. This combination strategy offers enhanced efficacy compared to the use of either compound alone.																

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA